Comparison Between Axial- and Lateral-viewing Capsule Endoscopy in Celiac Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03095573|
Recruitment Status : Unknown
Verified March 2017 by Luca Elli, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico.
Recruitment status was: Recruiting
First Posted : March 29, 2017
Last Update Posted : March 30, 2017
|Condition or disease||Intervention/treatment||Phase|
|Celiac Disease||Device: Lateral-viewing CapsoCam device Device: Axial-viewing capsule||Not Applicable|
The study will involve 25 patients with suspected complicated celiac disease , which for clinical reasons are referred for an evaluation of the small intestine by means of capsule endoscopic in order to screen/identify complications. Furthermore, patients under regular follow-up for a known complication of celiac disease (i.e. refractory celiac disease, ulcerative jejunoileitis) will also be enrolled.
Patients reffered to the Center for Prevention and Diagnosis of celiac disease at the research Hospital "Fondazione Cà Granda Ospedale Maggiore Policlinico" in Milan will be prospectively evaluated and consecutively enrolled in the study.
In agreement with international Guidelines, the diagnosis of celiac disease will be based on Presence of atrophy in the duodenal biopsy sampling (Marsh-Oberhuber type 3) and positive serology or genetic compatibility (in case of seronegative patients at diagnosis).
Patients at high risk of celiac disease complications are defined as
- subjects older than 50 years at the time of celiac disease diagnosis
- subjects with persistence / recurrence of gastrointestinal symptoms after at least 6 months of gluten-free diet
- subjects reporting poor compliance to the gluten-free diet
- subjects with alarm signs at diagnosis or during follow-up.
All enrolled patients will undergo examination of the small bowel by means of both endoscopic capsule devices (the axial-view PillCam SB3 and the lateral-view CapsoCam) on the same day at approximately 3 hours interval from one another, according to a protocol already validated in terms of security in other studies. The order of administration of the two different capsules, will be determined by a specific randomization sequence.
At the end of the examination, recorded data from the capsules will be acquired according to the following steps:
- For the axial-view capsule: removal of the recorder after 10 hours recording and/or after checking that the capsule has reached the cecum. The patient will also be instructed to retrieve the capsule from the stools in the hours / days following the examination as per standard protocol.
- For the lateral-view capsule, the patient will be given a specific kit for its retrieval and conservation. The recorded data will be downloaded after retrieval of the capsule.
The 50 videos will be reviewed by three experts operators (L.E., F.B. G.E.T.), blinded and in randomized order. The operators will evaluate the number of lesions detected by the two different types of capsule system (Primary endpoint) and the mean extension of the lesions detected, expressed as percentage of the total transit time of the capsule in the small intestine (Secondary endpoint)
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||25 participants|
|Intervention Model:||Crossover Assignment|
|Intervention Model Description:||Each enrolled patients will undergo examination of the small bowel by means of both endoscopic capsule devices (the axial-view PillCam SB3 and the lateral-view CapsoCam) on the same day at approximately 3 hours interval from one another. The order of administration of the two different capsules will be determined by a specific randomization sequence.|
|Masking:||Single (Outcomes Assessor)|
|Masking Description:||The videos will be reviewed by three experts operators blinded about the sequence of capsule examination administration|
|Official Title:||Prospective Randomized Comparison Between Axial- and Lateral-viewing Capsule Endoscopy Systems in Celiac Patients: a Pilot Study|
|Actual Study Start Date :||March 1, 2017|
|Estimated Primary Completion Date :||October 31, 2018|
|Estimated Study Completion Date :||February 28, 2019|
Experimental: Lateral-viewing capsule
Examination of the small bowel by means of the lateral-viewing CapsoCam device
Device: Lateral-viewing CapsoCam device
Small bowel capsule endoscopy examination with the Lateral-viewing CapsoCam device
Active Comparator: Axial-viewing capsule
Examination of the small bowel by means of the axial-viewing capsule
Device: Axial-viewing capsule
Small bowel capsule endoscopy examination with the Axial-viewing capsule device
- Lesions detected [ Time Frame: up to 24 hours, the time of progression of the capsule through the small bowel ]Mean number of lesions detected by the two different types of devices, expressed as diagnostic yield and total number of lesions
- Extension of the lesions [ Time Frame: up to 24 hours, the time of progression of the capsule through the small bowel ]Mean extension of the lesions detected, expressed as percentage of the total transit time of the capsule in the small intestine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03095573
|Contact: Luca Elli, MD, PhDfirstname.lastname@example.org|
|Contact: Federica Branchi, MDemail@example.com|
|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico||Recruiting|
|Milano, MI, Italy, 20122|
|Contact: Luca Elli, MD, PhD +390255033384 firstname.lastname@example.org|
|Sub-Investigator: Federica Branchi, MD|
|Sub-Investigator: Francesca Ferretti, MD|
|Sub-Investigator: Roberto Penagini, MD, Prof.|
|Sub-Investigator: Dario Conte, MD, Prof.|
|Irccs Policlinico San Donato||Active, not recruiting|
|San Donato Milanese, MI, Italy, 20097|
|Principal Investigator:||Luca Elli, MD, PhD||Fondazione IRCCS Ca´Granda Ospedale Maggiore Policlinico, Milano, Italy|